Muscular Dystrophy – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of muscular dystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of nine types of muscular dystrophy: Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), myotonic dystrophy (DM), congenital muscular dystrophy (CMD),1 distal muscular dystrophy (DD),1 Emery-Dreifuss muscular dystrophy (EDMD),1 facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD),1 and oculopharyngeal muscular dystrophy (OPMD),1 as well as the diagnosed incidence of DMD, together with annualized case counts projected to the national populations.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s muscular dystrophy forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with muscular dystrophy per year?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of muscular dystrophy over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the above-mentioned total number of diagnosed prevalent and incident cases for each forecast year, Clarivate Epidemiology provides 20 years of forecast data for the following subpopulations:
- Diagnosed prevalence of DMD by ambulatory status.
- Diagnosed prevalence of DMD by exon-skipping-amenable mutation status.
- Diagnosed prevalence of DMD with nonsense mutations.
- Diagnosed prevalence of DMD with cardiomyopathy.
- Diagnosed prevalence of DM by subtype.
- Diagnosed prevalence of DM1 by age of onset.
- Diagnosed prevalence of CMD by subtype.1
- Diagnosed prevalence of LGMD by subtype.1
Note: Coverage may vary by country.
1. Excluding Japan because of data unavailability.
Table of contents
- Muscular Dystrophy - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of muscular dystrophy)
- Diagnosed prevalent cases of Duchenne muscular dystrophy
- Diagnosed prevalent cases of Duchenne muscular dystrophy by exon-skipping pattern
- Diagnosed prevalent cases of Duchenne muscular dystrophy by nonsense mutation status
- Diagnosed prevalent cases of Duchenne muscular dystrophy by ambulatory status
- Diagnosed prevalent cases of Duchenne muscular dystrophy with cardiomyopathy
- Diagnosed incident cases of Duchenne muscular dystrophy
- Diagnosed prevalent cases of Becker muscular dystrophy
- Diagnosed prevalent cases of myotonic dystrophy
- Diagnosed prevalent cases of type 1 myotonic dystrophy
- Diagnosed prevalent cases of type 1 myotonic dystrophy by subtype
- Diagnosed prevalent cases of type 2 myotonic dystrophy
- Diagnosed prevalent cases of congenital muscular dystrophy
- Diagnosed prevalent cases of congenital muscular dystrophy by subtype
- Diagnosed prevalent cases of distal muscular dystrophy
- Diagnosed prevalent cases of Emery-Dreifuss muscular dystrophy
- Diagnosed prevalent cases of facioscapulohumeral muscular dystrophy
- Diagnosed prevalent cases of limb-girdle muscular dystrophy
- Diagnosed prevalent cases of limb-girdle muscular dystrophy by subtype
- Diagnosed prevalent cases of oculopharyngeal muscular dystrophy
- Drug-treated prevalent cases of Duchenne muscular dystrophy
- Risk/protective factors applied to disease forecast models
- Reference Materials
